Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens

被引：1

作者：

Serafin, Andrea ^{[1
]}

Cellini, Alessandro ^{[1
]}

Cavarretta, Chiara Adele ^{[1
]}

Ruocco, Valeria ^{[1
]}

Angotzi, Francesco ^{[1
]}

Zatta, Ivan ^{[1
]}

Frezzato, Federica ^{[1
]}

Bonaldi, Laura ^{[2
]}

Martines, Annalisa ^{[2
]}

Pravato, Stefano ^{[1
]}

Piazza, Francesco ^{[1
]}

Trentin, Livio ^{[1
]}

Visentin, Andrea ^{[1
]}

机构：

[1] Univ Padua, Dept Med, Hematol Unit, Via Nicolo Giustiniani 2, I-35128 Padua, PD, Italy

[2] Veneto Inst Oncol, Immunol & Mol Oncol Unit, IOV IRCCS, Padua, Italy

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 01期

关键词：

CK; high CK; MRD; venetoclax; CLL;

D O I：

10.1111/bjh.19517

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although the unfavourable prognostic role of complex karyotype (CK) in chronic lymphocytic leukaemia (CLL) patients treated with chemoimmunotherapy has been clarified, its impact on the outcome of patients being treated with novel targeted agents, and especially with venetoclax-based regimens, remains to be resolved. In fact, only few studies, utilizing data derived from clinical trials (e.g. MURANO, CLL14, GAIA-CLL13), specifically focus on this topic while real-word evidence is missing. In our real-life retrospective study conducted on 61 patients with CLL and treated with venetoclax-based regimens in any therapeutic line, we documented a remarkable lower progression-free survival in patients harbouring both CK and high CK, while overall response rate (including complete remissions and partial remissions) and overall survival are not affected by CK in our population.

引用

页码：189 / 193

页数：5

共 50 条

[31] Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting
Fakhri, Bita
Emechebe, Nnadozie
Manzoor, Beenish S.
Jawaid, Dureshahwar
Alhasani, Hasan
Edwards, Melanie
Tuncer, Hande H.
JCO ONCOLOGY PRACTICE, 2024, 20 (08)
[32] Q-TWiST in Venetoclax-Based Regimens in Elderly Patients with AML: A Quality-Adjusted
Hernandez Perez, Andrea Priscila
Cabello Modesto, Daniel
Demichelis, Roberta
BLOOD, 2022, 140 : 3220 - 3221
[33] The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia
Eyre, Toby A.
Roeker, Lindsey E.
Fox, Christopher P.
Gohill, Satyen H.
Walewska, Renata
Walter, Harriet S.
Forconi, Francesco
Broom, Angus
Arumainathan, Arvind
Brander, Danielle M.
Allan, John N.
Schuster, Stephen J.
Hill, Brian T.
Lansigan, Frederick
Cheson, Bruce D.
Lamanna, Nicole
Coombs, Catherine C.
Barr, Paul M.
Skarbnik, Alan P.
Shadman, Mazyar
Ujjani, Chaitra S.
Pearson, Laurie
Pagel, John M.
Jacobs, Ryan
Mato, Anthony R.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (06) : 918 - 923
[34] Functional and prognostic role of ZAP-70 in chronic lymphocytic leukaemia
Hamblin, AD
Hamblin, TJ
EXPERT OPINION ON THERAPEUTIC TARGETS, 2005, 9 (06) : 1165 - 1178
[35] INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA TREATED WITH IBRUTINIB
Wasik-Szczepanek, E.
Szymczyk, A.
Czabak, O.
Cioch, M.
Wach, M.
Podhorecka, M.
Sokolowska, B.
Pasiarski, M.
Kozinska, J.
Hus, I.
Szczepanek, D.
Kotwica, K.
Szczepanek, A.
Hus, M.
HAEMATOLOGICA, 2017, 102 : 722 - 722
[36] Detection and monitoring of t(11;14) in liquid biopsies from patients with relapsed/refractory multiple myeloma treated with venetoclax-based regimens
Li, Xiaotong
Saal, Lao H.
Brueffer, Christian
Chen, Yilun
Asklin, Johanna
Alvi, Saman
Venkatram, Srinivas
Ross, Jeremy A.
CANCER RESEARCH, 2023, 83 (07)
[37] In defence of the use of modern chemotherapy regimens for the treatment of patients with chronic lymphocytic leukaemia
Tam, C. S.
INTERNAL MEDICINE JOURNAL, 2009, 39 (12) : 858 - 859
[38] At-Home Care Program for Acute Myeloid Leukemia Induction Phase in Patients Treated with Venetoclax-Based Low-Intensity Regimens
Martinez-Roca, Alexandra
Jimenez-Vicente, Carlos
Merchan, Beatriz
Castano-Diez, Sandra
Zugasti, Ines
Brillembourg, Helena
Bataller, Alex
Guijarro, Francesca
Cortes-Bullich, Albert
Trigueros, Ana
Perez-Valencia, Amanda Isabel
Gallego, Cristina
Ballestar, Nuria
Rodriguez-Lobato, Luis Gerardo
Carcelero, Esther
Diaz-Beya, Marina
Esteve, Jordi
Fernandez-Aviles, Francesc
CANCERS, 2024, 16 (24)
[39] High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia (vol 135, pg 866, 2020)
Al-Sawaf, O.
Lilienweiss, E.
Bahlo, J.
BLOOD, 2022, 139 (25) : 3669 - 3669
[40] Complex Karyotype is a Stronger Predictor Than Del(17p) for an Inferior Outcome in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients Treated With Ibrutinib-Based Regimens
Thompson, Philip A.
O'Brien, Susan M.
Wierda, William G.
Ferrajoli, Alessandra
Stingo, Francesco
Smith, Susan C.
Burger, Jan A.
Estrov, Zeev
Jain, Nitin
Kantarjian, Hagop M.
Keating, Michael J.
CANCER, 2015, 121 (20) : 3612 - 3621

← 1 2 3 4 5 →